Company intelligence / Profile preview

Extrovis

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

Extrovis develops and manufactures complex generics and differentiated pharmaceutical products with a focus on liquid injectables, nanoemulsions, drug/device combinations, peptides, topicals (including oncology/hormonal), complex oral solids/liquids/suspensions. Several formulations are described as first-in-the-world. The company operates globally with EU GMP/US FDA-accredited manufacturing sites. Some programs have achieved regulatory approval in major markets[2][3][6].

Therapeutic areas: OncologyEndocrinologyImmunologyNeurologyInfectious Diseases
Modalities: Small moleculePeptidesDrug-device combinationInjectable (liquid injectables, nanoemulsions)Topical formulations (including oncology and hormonals)
Industry: Biotech

Beyond the preview

Go deeper on Extrovis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Extrovis.

Explore the full profile